ALS Research Collaboration
  • Home
  • About Us
    • Who we are
    • Our Approach
    • Our Team
    • Our History
  • Our Research
    • Research Focus
    • Participate
    • Studies
    • Current
    • Completed
    • All
    • Publications & Talks
    • Research Vignettes
  • News & Events
  • Support Us
    • Make a donation
  • Contact Us
Select Page

A roadmap to ALS prevention: strategies and priorities.

by Alexandra Grace | Oct 31, 2023

Benatar M, Goutman SA, Staats KA, Feldman EL, Weisskopf M, Talbott E, Dave KD, Thakur NM, Al-Chalabi A. A roadmap to ALS prevention: strategies and priorities. J Neurol Neurosurg Psychiatry. 2023 May;94(5):399-402. [PubMed Link]

Patient reported impact of symptoms in amyotrophic lateral sclerosis (PRISM-ALS): A national, cross-sectional study.

by Kyra Johnson | Oct 31, 2023

Zizzi C, Seabury J, Rosero S, Alexandrou D, Wagner E, Weinstein JS, Varma A, Dilek N, Heatwole J, Wuu J, Caress J, Bedlack R, Granit V, Statland JM, Mehta P, Benatar M, Heatwole C. Patient reported impact of symptoms in amyotrophic lateral sclerosis (PRISM-ALS): A...

Functional alterations in large-scale resting-state networks of amyotrophic lateral sclerosis: A multi-site study across Canada and the United States.

by Alexandra Grace | Aug 1, 2022

Bharti K, J Graham S, Benatar M, Briemberg H, Chenji S, Dupré N, Dionne A, Frayne R, Genge A, Korngut L, Luk C, Zinman L, Kalra S; Canadian ALS Neuroimaging Consortium (CALSNIC). Functional alterations in large-scale resting-state networks of amyotrophic lateral...

Mild motor impairment as prodromal state in amyotrophic lateral sclerosis: a new diagnostic entity.

by Kyra Johnson | Aug 1, 2022

Benatar M, Granit V, Andersen PM, Grignon AL, McHutchison C, Cosentino S, Malaspina A, Wuu J.  Mild motor impairment as prodromal state in amyotrophic lateral sclerosis: a new diagnostic entity.  Brain. Brain. 2022 Oct 21;145(10):3500-3508. Epub 2022 May 20. [PubMed...

Design of a randomized, placebo-controlled, phase 3 trial of tofersen initiated in clinically presymptomatic SOD1 variant carriers: the ATLAS Study.

by Kyra Johnson | Aug 1, 2022

Benatar M, Wuu J, Andersen PM, Bucelli RC, Andrews JA, Otto M, Farahany NA, Harrington EA, Chen W, Mitchell AA, Ferguson T, Chew S, Gedney L, Oakley S, Heo J, Chary S, Fanning L, Graham D, Sun P, Liu Y, Wong J, Fradette S.  Design of a randomized, placebo-controlled,...
« Older Entries
Next Entries »

Recent Posts

  • Landmark Study Identifies Novel Pre-Symptomatic Biomarkers and Accelerates Progress Towards ALS Prevention
  • July 26, 2026: Miami Marlins Game
  • Feature: UHealth’s Qalsody Clinic Provides Cutting-Edge Care for ALS Patients
  • The New York Times Feature: In a Milestone for A.L.S., a Treatment Helps Some Patients Improve
  • CReATe Author Series Ep. 18 – Dr. Michael Benatar on MMI as a prodromal stage of ALS

Recent Comments

    Latest News

    07/27/26

    Landmark Study Identifies Novel Pre-Symptomatic Biomarkers and Accelerates Progress Towards ALS Prevention

    07/22/26

    July 26, 2026: Miami Marlins Game

    05/26/26

    Feature: UHealth’s Qalsody Clinic Provides Cutting-Edge Care for ALS Patients

    How You Can Help

    Participate in Research

    Make a Donation

    ALS Research Collaboration
    University of Miami,
    Department of Neurology
    1120 NW 14th Street
    Miami, FL 33136

    Search our site

    About Us

    • Who We Are
    • Our Approach
    • Our Team
    • Our History

    Our Research

    • Research Focus
    • Participate
    • All Studies
    • Publications and Talks
    • Research Vignettes

    Support Us

    • Make a Donation

    Search our site

    Copyright 2024 ALS Research Collaboration at University of Miami. All Rights Reserved. Branding by MOK2